



CLAIMS:

1. A compound having the formula:










where



$R_2 = \text{H, C}_1\text{-C}_6 \text{ alkyl, cycloalkyl}$

(I)



Dashed lines: optional; conformational constraint by $(\text{CH}_2)_n, n=1-3, R' = \text{H or O(=)}$

2. A compound according to claim 1 wherein: $R_1, R_2 = H$; $W = (CH_2)_4$; $X = -CH(OH)CO-$; $R_5 = H$; $R_6 = 5-N(CH_3)_2$; $Y = -CH=CH-$; and $Z = SO_2NHCH_2CO$.
- 5 3. A pharmaceutical composition for attenuating the effects of an opiate addiction, opiate dependence, opiate tolerance, opiate related abstinence syndrome, nicotine addiction and obesity comprising said compound of claim 1 in an amount sufficient to effect said attenuation, together with a pharmaceutically acceptable carrier.
- 10 4. A method of treating an opiate addiction, opiate dependence, opiate tolerance, opiate related abstinence syndrome, nicotine addiction and obesity comprising administering to a mammal in need of such treatment an amount of said compound according to claim 1 sufficient to effect said treatment.
- 15 5. A method of treating an opiate dependence comprising administering to a mammal in need of such treatment an amount of said compound according to claim 1 sufficient to effect said treatment.
- 20 6. A method of treating an opiate tolerance comprising administering to a mammal in need of such treatment an amount of said compound according to claim 1 sufficient to effect said treatment.
7. A method of treating an opiate related abstinence syndrome comprising administering

to a mammal in need of such treatment an amount of said compound according to claim 1 sufficient to effect said treatment.